Journal article
Predictors of consent to pharmacogenomics testing in the IDEAL study
AB Jazwinski, PJ Clark, AJ Thompson, SC Gordon, EJ Lawitz, S Noviello, CA Brass, LD Pedicone, JK Albrecht, MS Sulkowski, AJ Muir
Pharmacogenetics and Genomics | LIPPINCOTT WILLIAMS & WILKINS | Published : 2013
Abstract
INTRODUCTION: Pharmacogenomic testing is important in developing individualized therapeutic approaches. In the phase 3 IDEAL (Individualized Dosing to Assess Optimal Pegylated Interferon Therapy) clinical trial, a subset of patients receiving peginterferon and ribavirin for treatment of chronic hepatitis C agreed to provide blood samples for genetic testing. Genome-wide association studies subsequently identified associations between IL28B polymorphism and sustained virologic response, and ITPA polymorphism and ribavirin-associated anemia. OBJECTIVE: To characterize the groups of patients who accepted or declined pharmacogenomic testing in the IDEAL study. METHODS: Clinical and demographic f..
View full abstractGrants
Awarded by National Institute of Diabetes and Digestive and Kidney Diseases
Funding Acknowledgements
[ "The IDEAL study was sponsored by Schering-Plough (now Merck & Co. Inc.).", "Editorial assistance was provided by Tim Ibbotson, PhD, and Bianca Ruzicka, PhD, of ApotheCom (Yardley, PA). This assistance was funded by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co. Inc., Whitehouse Station, NJ.", "A.B.J. received the Duke Training Grant in Digestive Diseases and Nutrition during the period from 1 July 2010 to 30 June 2011 (#NIH 5T32DK007568-20)." ]